Literature DB >> 2140339

Inhibition of Streptococcus mutans glucosyltransferase activity by antiserum to a subsequence peptide.

M T Dertzbaugh1, F L Macrina.   

Abstract

An antigenic 15-amino-acid peptide sequence (gtfB.1) from the glucosyltransferase B enzyme of the cariogenic bacterium Streptococcus mutans GS-5 was identified previously from the genetic fusion of this sequence to the B subunit of cholera toxin. The resulting chimeric protein was used to raise antiserum in rabbits. This antiserum was shown to recognize the native glucosyltransferase enzyme and to inhibit its activity. The antiserum inhibited the synthesis of water-soluble glucan by approximately 40% and the synthesis of water-insoluble glucan by greater than 90%. The antiserum was shown to partially inhibit fructosyltransferase activity as well. The ability of this antipeptide antiserum to inhibit several enzymes from S. mutans suggests that these enzymes share an epitope related to enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140339      PMCID: PMC258662          DOI: 10.1128/iai.58.6.1509-1513.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Sequence analysis of the Streptococcus mutans fructosyltransferase gene and flanking regions.

Authors:  T Shiroza; H K Kuramitsu
Journal:  J Bacteriol       Date:  1988-02       Impact factor: 3.490

2.  Cholera toxin B-subunit gene fusion: structural and functional analysis of the chimeric protein.

Authors:  M T Dertzbaugh; D L Peterson; F L Macrina
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

3.  High resolution two-dimensional electrophoresis of proteins.

Authors:  P H O'Farrell
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

4.  Inhibition of glucosyltransferase activity by antisera to known serotypes of Streptococcus mutans.

Authors:  R T Evans; R J Genco
Journal:  Infect Immun       Date:  1973-02       Impact factor: 3.441

5.  Plasmid vectors for constructing translational fusions to the B subunit of cholera toxin.

Authors:  M T Dertzbaugh; F L Macrina
Journal:  Gene       Date:  1989-10-30       Impact factor: 3.688

6.  Isolation and characterization of the Streptococcus mutans gtfD gene, coding for primer-dependent soluble glucan synthesis.

Authors:  N Hanada; H K Kuramitsu
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

7.  Oral immunization of humans with Streptococcus sobrinus glucosyltransferase.

Authors:  D J Smith; M A Taubman
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

8.  Sucrose 6-alpha-D-glucosyltransferase from Streptococcus sobrinus: characterization of a glucosyl-enzyme complex.

Authors:  G Mooser; K R Iwaoka
Journal:  Biochemistry       Date:  1989-01-24       Impact factor: 3.162

9.  Homology of glucosyltransferase gene and protein sequences from Streptococcus sobrinus and Streptococcus mutans.

Authors:  R R Russell; T Shiroza; H K Kuramitsu; J J Ferretti
Journal:  J Dent Res       Date:  1988-03       Impact factor: 6.116

10.  Sequence analysis of the gtfC gene from Streptococcus mutans GS-5.

Authors:  S Ueda; T Shiroza; H K Kuramitsu
Journal:  Gene       Date:  1988-09-15       Impact factor: 3.688

View more
  11 in total

1.  Antibody to glucosyltransferase induced by synthetic peptides associated with catalytic regions of alpha-amylases.

Authors:  D J Smith; R L Heschel; W F King; M A Taubman
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein.

Authors:  C Jespersgaard; P Zhang; G Hajishengallis; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

3.  Inhibition of glucosyltransferase activities of Streptococcus mutans by a monoclonal antibody to a subsequence peptide.

Authors:  J S Chia; R H Lin; S W Lin; J Y Chen; C S Yang
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

4.  Analysis of a DNA polymorphic region in the gtfB and gtfC genes of Streptococcus mutans.

Authors:  J S Chia; S W Lin; T Y Hsu; J Y Chen; H W Kwan; C S Yang
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

5.  Protective immunity against Streptococcus mutans infection in mice after intranasal immunization with the glucan-binding region of S. mutans glucosyltransferase.

Authors:  C Jespersgaard; G Hajishengallis; Y Huang; M W Russell; D J Smith; S M Michalek
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

6.  Immunogenicity and protective immunity induced by synthetic peptides associated with a catalytic subdomain of mutans group streptococcal glucosyltransferase.

Authors:  D J Smith; B Shoushtari; R L Heschel; W F King; M A Taubman
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

7.  Immunological characteristics of a synthetic peptide associated with a catalytic domain of mutans streptococcal glucosyltransferase.

Authors:  D J Smith; M A Taubman; W F King; S Eida; J R Powell; J Eastcott
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

8.  Immunologic characteristics of a Streptococcus mutans glucosyltransferase B sucrose-binding site peptide-cholera toxin B-subunit chimeric protein.

Authors:  P Laloi; C L Munro; K R Jones; F L Macrina
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

9.  Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines.

Authors:  M T Dertzbaugh; C O Elson
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

Review 10.  Structure-function relationships of glucansucrase and fructansucrase enzymes from lactic acid bacteria.

Authors:  Sacha A F T van Hijum; Slavko Kralj; Lukasz K Ozimek; Lubbert Dijkhuizen; Ineke G H van Geel-Schutten
Journal:  Microbiol Mol Biol Rev       Date:  2006-03       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.